Lee Kallenbach, PhD, MPH
Lee is an accomplished research epidemiologist with experience spanning public health, healthcare quality, and clinical health outcomes.
AREA OF EXPERTISE
Real-world EHR data studies Population health Type-2 diabetes treatmentLee is an accomplished research epidemiologist with experience spanning public health, healthcare quality, and clinical health outcomes. He serves as a senior clinical consultant and leads research studies leveraging Veradigm data assets in electronic health records (EHRs), administrative claims, and patient registries.
Dr. Kallenbach leads scientific engagements from conceptualization through design, implementation, and interpretation and publication. He has interest in study design methods and the integration of information from multiple sources to provide deeper understanding of population and social determinants of health. Prior to joining Veradigm, Dr. Kallenbach worked with EHR data in healthcare outcomes research at Practice Fusion, Quintiles, and General Electric Healthcare.
Dr. Kallenbach has held positions in quality improvement, academia, healthcare, and public health. He has presented at scientific meetings, published articles, reviewed manuscripts, served on grant review study committees, and has taught graduate level courses in epidemiology. He holds degrees in Epidemiology (MPH) and Occupational Health (PhD) from the University of Michigan School of Public Health.
Read articles by this expert
A Real-World Study from Amgen and Veradigm®: Early Use of Erenumab in US Clinical Practice
ReadReal-World Use of IDegLira in US Clinical Practice: A Safety and Effectiveness Study from the Medical College of Wisconsin, Novo Nordisk, and Veradigm®
ReadReal-World Practice Study by AstraZeneca and Veradigm - LAMA LABA COPD Treatment Study
ReadNew Study from AstraZeneca and Veradigm on COPD - Blood Eosinophil Count
ReadReferences to published articles by this expert
- Chia V, Bogdanov A, Yusuf A, Kallenbach L. Characteristics of migraine patients with Migraine Disability Assessment (MIDAS) scores in real-world clinical practice. Cephalalgia Reports. 2020;3:2515816320928463.
- Mues KE, Bogdanov AN, Monda KL, Yedigarova L, Liede A, Kallenbach L. How well can familial hypercholesterolemia be identified in an electronic health record database? Clinical epidemiology. 2018;10:1667-77.
- Kallenbach L, Shui AM, Cheng WY, Fan T, Hu W, Zichlin ML, et al. Predictors and Clinical Outcomes of Treatment Intensification in Patients with Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2018;24(9):805-14.
- Yu M, Mody R, Landó LF, Shui A, Kallenbach L, Slipski L, et al. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients with Type 2 Diabetes. Clinical therapeutics. 2017;39(12):2399-408.